TQB2934 injection

DRUG3 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

Conditions

Multiple MyelomaSystemic Light Chain Amyloidosis

Phase 1

A Clinical Trial of TQB2934 for Injection in Multiple Myeloma Subjects

RecruitingNCT05646758

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Multiple Myeloma

Start: 2023-03-17End: 2025-10-31Target: 140Updated: 2024-03-18

Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients

RecruitingNCT07266116

Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.Systemic Light Chain Amyloidosis

Start: 2025-12-26End: 2029-11-01Target: 70Updated: 2026-05-08

Phase 3

Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma

Not yet recruitingNCT07569757

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Multiple Myeloma

Start: 2026-06-01End: 2030-12-01Target: 260Updated: 2026-05-08

Related Papers

Updated results of TQB2934, a novel 2+1 BCMA × CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma: A phase I study

Blood2025-11-03

Initial Results from a Phase 1 Study of TQB2934, a BCMA × CD3 Bispecific Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple

Blood2024-11-05